MedTrace Logo

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

NCT00251368 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2011-03-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.

Conditions

  • Leukemia, Myelocytic, Acute
  • Acute Lymphocytic Leukemia

Interventions

DRUG

9-Aminocamptothecin (9-AC)

Sponsors & Collaborators

Principal Investigators

  • Richard Stone, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-01-31
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00251368 on ClinicalTrials.gov